ERBB2 and gastric cancer: In conclusion, This study lends support to the potential of IBI315 as a promising bispecific antibody‐based immunotherapeutic approach in preclinical assessments, thereby expanding the therapeutic options available for patients with Her2‐positive gastric cancer.